Clinical trials: Second-Line
Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma
Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer
This is a single-arm, Phase 2 clinical trial (PERSEUS TRIAL / LACOG 1924) evaluating the efficacy, safety, and tolerability of sacituzumab tirumotecan (sac-TMT; MK-2870) as a second-line treatment for patients with advanced or…
- Trial name
- PERSEUS (NCT07815197)
- Testing
- Sacituzumab Tirumotecan
- Where
- 11 sites in Brazil
- Volunteers
- 37 people
- Sponsor
- Latin American Cooperative Oncology Group
Biliary Tract Cancer
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus nanoliposomal-irinotecan, 5-fluorouracil, and leucovorin for…
- Trial name
- NCT03785873
- Testing
- Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Michigan Rogel Cancer Center
Her2-negative Metastatic Breast Cancer, Her2-negative Locally Advanced Breast Cancer
Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer
The purpose of this study is Examination of the superiority of a combination of vinorelbine with the mTOR Inhibitor Everolimus vs. vinorelbine monotherapy for second-line treatment in advanced breast cancer.
- Trial name
- VicTORia (NCT01520103)
- Testing
- Vinorebine, Everolimus, Vinorelbine
- Where
- Germany
- Volunteers
- 139 people
- Sponsor
- AIO-Studien-gGmbH
Non Small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
International multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced…
- Trial name
- DOMINUS (NCT03288870)
- Testing
- BCD-100, Docetaxel
- Where
- 8 sites in Belarus, Russia
- Volunteers
- 218 people
- Sponsor
- Biocad
Helicobacter Pylori Eradication
Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication
This trial assessed the efficacy of potassium competetor acid blocker (P-CAB) in the eradication of H.pylori
- Trial name
- P-CABs (NCT06101420)
- Testing
- Vonoprazan
- Where
- Egypt
- Volunteers
- 232 people
- Sponsor
- Ain Shams University
Breast Cancer
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and…
- Trial name
- BioItaLEE (NCT03439046)
- Testing
- Ribociclib, Letrozole, Alpelisib
- Where
- 41 sites in Italy
- Volunteers
- 287 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Mesothelioma
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.
- Trial name
- NCT01649024
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Cholangiocarcinoma
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them…
- Trial name
- EPIC (NCT02452970)
- Testing
- RRx-001, Gemcitabine and cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EpicentRx, Inc.
Multiple Myeloma
Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
The purpose of this study is to quantify the burden of treatment in relapsed or refractory multiple myeloma in patients receiving lenalidomide after one prior treatment for myeloma.
- Trial name
- NCT01430546
- Where
- Sweden
- Volunteers
- 133 people
- Sponsor
- Hareth Nahi
First or Second Line HER2-negative Breast Cancer, Metastatic Disease Without Bone Metastasis
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
- Trial name
- MACS1295 (NCT01129336)
- Testing
- Zoledronic acid, Standard Therapy
- Where
- 33 sites in United States
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC
This study is for patients with cancer of the prostate gland that has metastasized or spread outside the prostate to other parts of the body.
- Trial name
- NCT00327340
- Testing
- custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel
- Where
- 10 sites in Canada
- Volunteers
- 70 people
- Sponsor
- Achieve Life Sciences
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be eligible to be enrolled in this study.
- Trial name
- IPoD-790 (NCT04790474)
- Testing
- ixazomib-pomalidomide-dexamethasone
- Where
- 7 sites in Israel
- Volunteers
- 61 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression following first-line treatment with bevacizumab plus sintilimab for…
- Trial name
- NCT07537985
- Testing
- Lenvatinib, Regorafenib, PD-1 Inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Adrenocortical Carcinoma
Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients
The study is designed as a Phase II, prospective, non randomized, open-label, single arm, multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to complete surgical resection and progressing to…
- Trial name
- PAXO (NCT00786110)
- Testing
- Sorafenib, Paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy
Small Cell Lung Cancer
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of…
- Trial name
- NCT02038647
- Testing
- Alisertib, Paclitaxel
- Where
- 61 sites in United States, Belgium and 8 more
- Volunteers
- 178 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Renal Cell
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
- Trial name
- NCT04626518
- Testing
- Pembrolizumab, MK-4830, Belzutifan
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 263 people
- Sponsor
- Merck Sharp & Dohme LLC
Age Related Macular Degeneration
Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself
The purpose of this study is to demonstrate that Visudyne-Lucentis-dexamethasone (V-L-D) triple therapy will give similar efficacy and safety results as Lucentis monotherapy.
- Trial name
- NCT00457678
- Testing
- Visudyne, Lucentis, Dexamethasone
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Gastric or Esophagogastric Junction Adenocarcinoma
Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
In order to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel as second-line treatment for recurrent metastatic gastric or esophagogastric junction adenocarcinoma with EGFR over-expression, investigators…
- Trial name
- NOTABLE-307 (NCT05978050)
- Testing
- nimotuzumab plus paclitaxel
- Where
- China
- Volunteers
- 354 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Immunotherapy combined with anti-angiogenic therapy can achieve better results in patients with second-line and above small cell lung cancer
- Trial name
- NCT04192682
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changzhou Cancer Hospital of Soochow University
Gastric Carcinoma
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer
This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.
- Trial name
- TESEGAST (NCT01573468)
- Testing
- Tesetaxel, Capecitabine
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 580 people
- Sponsor
- Genta Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.